Hiriart Y, Rossi A H, Biedma M E, Errea A J, Moreno G, Cayet D, Rinaldi J, Blancá B, Sirard J C, Goldbaum F, Berguer P, Rumbo M
Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP), La Plata, Argentina.
Fundación Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Protein Sci. 2017 May;26(5):1049-1059. doi: 10.1002/pro.3151. Epub 2017 Mar 16.
Aiming to combine the flexibility of Brucella lumazine synthase (BLS) to adapt different protein domains in a decameric structure and the capacity of BLS and flagellin to enhance the immunogenicity of peptides that are linked to their structure, we generated a chimeric protein (BLS-FliC131) by fusing flagellin from Salmonella in the N-termini of BLS. The obtained protein was recognized by anti-flagellin and anti-BLS antibodies, keeping the oligomerization capacity of BLS, without affecting the folding of the monomeric protein components determined by circular dichroism. Furthermore, the thermal stability of each fusion partner is conserved, indicating that the interactions that participate in its folding are not affected by the genetic fusion. Besides, either in vitro or in vivo using TLR5-deficient animals we could determine that BLS-FliC131 retains the capacity of triggering TLR5. The humoral response against BLS elicited by BLS-FliC131 was stronger than the one elicited by equimolar amounts of BLS + FliC. Since BLS scaffold allows the generation of hetero-decameric structures, we expect that flagellin oligomerization on this protein scaffold will generate a new vaccine platform with enhanced capacity to activate immune responses.
为了将布鲁氏菌核黄素合酶(BLS)在十聚体结构中适应不同蛋白质结构域的灵活性与BLS和鞭毛蛋白增强与其结构相连的肽的免疫原性的能力相结合,我们通过将来自沙门氏菌的鞭毛蛋白融合到BLS的N端,生成了一种嵌合蛋白(BLS-FliC131)。所获得的蛋白能被抗鞭毛蛋白和抗BLS抗体识别,保持了BLS的寡聚化能力,且不影响通过圆二色性测定的单体蛋白组分的折叠。此外,每个融合伴侣的热稳定性得以保留,这表明参与其折叠的相互作用不受基因融合的影响。此外,无论是在体外还是在使用TLR5缺陷动物的体内,我们都能确定BLS-FliC131保留了触发TLR5的能力。BLS-FliC131引发的针对BLS的体液反应比等摩尔量的BLS + FliC引发的反应更强。由于BLS支架允许生成异源十聚体结构,我们预计鞭毛蛋白在该蛋白质支架上的寡聚化将产生一个具有增强免疫反应激活能力的新疫苗平台。